Abstract:AbstractRadiotherapy is a major treatment modality used to treat muscle-invasive bladder cancer, with patient outcomes similar to surgery. However, radioresistance is a significant factor in treatment failure. Cell-free extracts of muscle-invasive bladder tumors are defective in nonhomologous end-joining (NHEJ), and this phenotype may be used clinically by combining radiotherapy with a radiosensitizing drug that targets homologous recombination, thereby sparing normal tissues with intact NHEJ. The response of the homologous recombination protein RAD51 to radiation is inhibited by the small-molecule tyrosine kinase inhibitor imatinib. Stable RT112 bladder cancer Ku knockdown (Ku80KD) cells were generated using short hairpin RNA technology to mimic the invasive tumor phenotype and also RAD51 knockdown (RAD51KD) cells to show imatinib's pathway selectivity. Ku80KD, RAD51KD, nonsilencing vector control, and parental RT112 cells were treated with radiation in combination with either imatinib or lapatinib, which inhibits NHEJ and cell survival assessed by clonogenic assay. Drug doses were chosen at approximately IC40 and IC10 (nontoxic) levels. Imatinib radiosensitized Ku80KD cells to a greater extent than RAD51KD or RT112 cells. In contrast, lapatinib radiosensitized RAD51KD and RT112 cells but not Ku80KD cells. Taken together, our findings suggest a new application for imatinib in concurrent use with radiotherapy to treat muscle-invasive bladder cancer. Cancer Res; 73(5); 1611–20. ©2012 AACR.

Supplementary Table 1, Figures 1 - 2 from Imatinib Radiosensitizes Bladder Cancer by Targeting Homologous Recombination

Data from Imatinib Radiosensitizes Bladder Cancer by Targeting Homologous Recombination

Imatinib Radiosensitizes Bladder Cancer by Targeting Homologous Recombination.

Supplementary Figure S2 from Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase

Supplementary Table 4 from ATR Inhibition is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer

Supplementary Table S4 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Supplementary Figures from Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining

Supplementary Figure Legends from Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor

Supplementary Figure Legends from Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors

Supplementary Tables 1-5 from A Small Interfering RNA Screen of Genes Involved in DNA Repair Identifies Tumor-Specific Radiosensitization by POLQ Knockdown

Supplementary Figures from RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer

Supplementary Tables from HER2/EGFR–AKT Signaling Switches TGFβ from Inhibiting Cell Proliferation to Promoting Cell Migration in Breast Cancer

Supplementary Tables 1-4 from Targeting FBW7 As a Strategy to Overcome Resistance to Targeted Therapy in Non–Small Cell Lung Cancer

Supplementary Tables from CBX8 Exhibits Oncogenic Activity Via AKT/β-Catenin Activation in Hepatocellular Carcinoma

Supplementary Information from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma

Supplementary Figure 4 from Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer

Supplementary Figure 7 from Tankyrase and the Canonical Wnt Pathway Protect Lung Cancer Cells from EGFR Inhibition

Supplementary Figures S1-S2 from Integrin α<sub>v</sub>β<sub>3</sub>-Targeted Radioimmunotherapy of Glioblastoma Multiforme

Supplementary Figure S2 from Concurrent Alterations in <i>tert</i>, <i>kdm6a</i>, and the BRCA Pathway in Bladder Cancer

Supplementary Table S1 from Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer

Supplementary Figure 5 from PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer